An international study of the quality of life of adult patients treated with home parenteral nutrition by Baxter, Janet P et al.
1 
 
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 
license http://creativecommons.org/licenses/by-nc-nd/4.0/ 
 
An international study of the quality of life of adult patients treated with home parenteral 
nutrition 
Janet P. Baxtera, Peter P. Fayersb, Federico Bozzettic, Darlene Kellyd, Francisca Jolye, Jon 
Shafferf, Getty Huisman-de Waalg, Geert Wanteng, Cora Jonkersg, Christina Cuerdah, Paul 
Thuli, Andre van Gossumj, Stanislaw Klekk, Malgoratza Lyszkowskal, Marie-France 
Boudreaultm, Alain Gilbertm, P Manon Jobinm, Michael Staunn, Lyn Gillanderso, Alastair 
Forbesp, Margie O’Callaghanq, Marion O’Connorr, Linda Santarpias, Pilar Gomez Enterriat , 
Daniele Giardiellou, Cinzia Brunelliv,w, Luigi Marianiu, and Loris Pironix , Home Artificial 
Nutrition and Chronic Intestinal Failure special interest group of the European Society for 
Clinical Nutrition and Metabolism (ESPEN). 
aDepartment of  Nutrition and Dietetics, Kings Cross Hospital, Dundee, UK, bDepartment of 
Public Health, University of Aberdeen, UK, cSurgeon and oncologist, Milan, Italy, dOley 
Foundation for Home Parenteral and Enteral Nutrition, Albany, New York, USA, eCentre for 
Gastroenterology and Nutrition Support, Hôpital Beaujon, Paris, fIntestinal Failure Unit, 
Salford Royal Hospital, Manchester, UK, gRadboud University Nijmegen Medical Centre, 
Amsterdam, The Netherlands, hHospital General Universitario Gregorio, Maranon, Madrid, 
Spain, iCharité University Hospital, Berlin, Germany, jMedico-Surgical Department of 
Gastroenterology, Hôpital Erasme, Brussels, Belgium, kGeneral and Oncology Surgery 
Unit, Intestinal Failure Center, Stanley Dudrick’s Memorial Hospital, Skawina, Poland, lThe 
Children’s Memorial Hospital, Warsaw, Poland, mDepartment of Surgery, Centre 
Hospitalier Universitaire de Québec, Canada, nDepartment of Gastroenterology, 
2 
 
Rigshospitalet, Denmark, oNutrition Services, Auckland City Hospital, New Zealand, p 
Norwich Medical School, University of East Anglia, Norwich, UK, qFlinders Medical Centre, 
Bedford Park, Australia, rNutrition and Dietetics, John Radcliffe Hospital, Oxford, UK, 
sClinical Nutrition and Internal Medicine, Department of Clinical and Experimental 
Medicine, Federico II University, Naples, Italy, tHospital Central,  de Asturias, Oviedo, 
Spain, uUnit of Medical Statistics, Biometry, Bioinformatics, Fondazione IRCCS Istituto 
Nazionale dei Tumori, Milan, Italy;  vPalliative Care, Pain Therapy and Rehabilitation Unit, 
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; wEuropean Palliative Care 
Research Centre (PRC), Department of Cancer Research and Molecular Medicine, 
Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, 
Norway,  xCentre for Chronic Intestinal Failure, Department of Digestive System, St. 
Orsola-Malpighi Hospital, University of Bologna, Italy. 
 
Short title: Quality of life in HPN. 
 
Address for correspondence:  Dr Janet P. Baxter,  
Department of Nutrition and Dietetics,  
Kings Cross Hospital, 
Dundee, UK 
janetbaxter@nhs.net 
+44 1382 596993 
 
3 
 
Keywords: Home parenteral nutrition; quality of life; patient reported outcomes; intestinal 
failure. 
4 
 
Abstract 
 
Background and aims: Home parenteral nutrition-quality of life (HPN-QOL©) is a self-
assessment tool for the measurement of QOL in patients on HPN. The aims of this study 
were: to re-assess the basic psychometric properties of the HPN-QOL©  in a multinational 
sample of adult patients; to provide a description of QOL dimensions by short and long 
HPN treatment duration; to explore clinical factors potentially associated to QOL scores. 
Methods: Patients (n=699) from 14 countries completed the HPN-QOL©. The 
questionnaires were analysed to evaluate data completeness, convergent /discriminant 
validity and internal-consistency reliability. The association of overall QOL and HPN 
treatment duration as well as other clinical factors were investigated using multivariable 
linear regression models. 
Results: The analysis of the multitrait-scaling and internal consistency indicates a good fit 
with the questionnaire structure for most items. Item discriminant validity correlation was 
satisfactory and psychometric evaluation of the HPN-QOL© in the different English, French 
and Italian language patient sub-groups confirmed psychometric equivalence of the three 
questionnaire versions. The results of the multivariable linear regression showed that QOL 
scores were significantly associated with HPN duration (better in long-term), underlying 
disease (better in Crohn’s disease and mesenteric ischemia) and living status (worse in 
living alone) and, after adjusting for the other factors, with the number of days of HPN 
infusion per week.   
Conclusions: The HPN-QOL©, is a valid tool for measurement of QOL in patients on HPN, 
to be used in the clinical practice as well as in research. 
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Introduction  
Intestinal failure is defined as “the reduction of gut function below the minimum necessary 
for the absorption of macronutrients and/or water and electrolytes, such that intravenous 
supplementation is required to maintain health and/or growth” (1). Home parenteral 
nutrition (HPN) is the primary therapy of chronic intestinal failure (CIF) (2). The main aims 
of HPN are to increase long term survival of patients who may otherwise die of malnutrition 
or dehydration or should otherwise be confined to hospital and, consequently, to improve, 
quality of life (QOL) and to allow socio-economic rehabilitation (3). Although patients on 
HPN may not achieve complete return to normality, scores can improve compared to pre-
HPN (4). 
Although HPN is a life-saving therapy for patients with CIF, it does involve the infusion of 
nutrients into a central vein, and can radically change the life of patients who may be faced 
with on-going symptoms of the underlying condition but also live a complex, technology-
dependent lifestyle (5). It is a time-consuming, invasive therapy used in patients who often 
have physical problems and who have to face many psychological difficulties as well. 
Anxiety and fear are common reactions to the threat of potentially life-threatening 
complications of treatment such as severe infection, thrombosis and liver failure (6), which 
realistically can still occur. Depression, anger, negative self-image and social limitations 
are frequently reported. Depression has been seen in up to 65% of patients on HPN and 
may have serious consequences for their therapy as it has been shown to lead to less 
careful catheter care and social impairment in 55% (7). All of these factors may impact on 
QOL. Severe fatigue has been reported as one of the most frequent complaints – in up to 
63% of HPN patients (8), which in turn consistently affect daily activities such as work and 
leisure. 
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In 2012, the period prevalence of HPN in 16 European countries was estimated to range 
from 3.25 to 66 patients per million of the population (9). The most common indication for 
HPN in adults is short bowel arising from underlying diseases such as mesenteric 
ischemia and Crohn’s disease; motility disorders and bowel obstruction due to cancer (7). 
About 60-79% of patients in USA and Europe receiving HPN survive for five years or more. 
At 10 years 84% are still dependent on HPN and a significant number live  20 years or 
longer (8-14). In 2009 ESPEN published guidelines for the use of HPN in adults (15) and 
recognised the lack of studies describing QOL in HPN patients using disease-specific 
tools; it was noted that measurement of QOL should be patient-based rather than the 
clinician’s perspective.  
The HPN-QOL©, a self-assessment tool for measurement of QOL in patients on HPN, was 
originally devised within the Home Artificial Nutrition and Chronic Intestinal Failure 
(HAN&CIF) special interest group of the European Society for Clinical Nutrition and 
Metabolism (ESPEN). It underwent psychometric validation in a small sample of English 
patients and was then translated into Danish, Dutch, French, German, Italian, Polish and 
Spanish to enable international use (16).  
Hence there is the need to assess the basic psychometric performance of the 
questionnaire in a larger number of patients and with translations into other languages, as 
well as to provide a description of QOL dimensions in a sample of patients from different 
European countries. Moreover it was deemed interesting to explore factors that are 
significantly correlated with patterns/items of QOL. 
The aims of the present study are: 
1. to re-assess basic psychometric properties of the HPN-QOL© in a multinational 
sample and explore differences across the three most widely-spoken languages in 
our sample: English, French and Italian; 
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2. to provide a description of QOL dimensions in a sample of international patients, 
stratified by short and long HPN treatment duration;  
3. to explore clinical factors associated with reported QOL. 
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Methods 
Study design 
This is a cross-sectional observational multicentre study promoted by the ESPEN 
HAN&CIF working group in fourteen European, North American and Australian countries. 
The research was also supported by the Scientific Committee of ESPEN which assigned a 
grant to the principal investigator (JB) of the study. Adult patients were recruited from 
January to December 2010 and were eligible if they were discharged from adult hospital 
services on HPN. Patients were excluded if they were unable to complete the 
questionnaire (either self-administered or at an interview) because of mental impairment. 
Quality of life measure and data collection procedure 
The HPN-QOL© questionnaire was developed as a treatment specific instrument for the 
assessment of QOL in patients treated with HPN. It has been translated into Danish, 
Dutch, French, German, Italian, Polish and Spanish, using forward-backward methodology 
(16). The French translation was adapted for use in Belgium and French-speaking Canada 
and the English version adapted for use in the US and Canada. Psychometric 
small-sample validation of the English version confirmed the scale structure of the 
questionnaire (17). 
The questionnaire contains 7 multi-item functional scales and 1 single-item functional 
scale, as well as 6 multi-item and 3 single-item symptom scale (17). The functional scales 
include General Health (GH), Ability to Holiday or Travel (HT), Coping (CO), Physical 
Function (PF), Ability to Eat and Drink (ED), Employment (EM), Sexual Function (SX), and 
Emotional Function (EF); for these scales, a high score indicates a high level of 
functioning. The symptom or problem scales, in which a high score represents high 
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severity or more problems, include Body Image (BI), Immobility (IM), Fatigue (FA), Sleep 
Pattern (SP), Gastrointestinal Symptoms (GI), other Pain (PA), Presence or Absence of a 
Stoma (ST), Financial Issues (FI), and Weight (WT). Two questions relate to nutrition 
teams and the availability of an ambulatory pump for infusion of HPN, in which a high 
score represents a good outcome. The questionnaire concludes with three 0-10 numerical 
rating scales (NRS) where high scores indicate high QOL. The first is a global QOL 
question and the other two respectively assess the effect of the underlying illness and of 
the HPN on overall QOL. The complete English version of the questionnaire can be found 
in the appendix of a previously published paper (17). 
The questionnaire was self completed by the patients, either at a scheduled outpatient visit 
or at home after mail delivery.  
Socio-demographic and clinical data including age, gender, educational level, marital and 
employment status, underlying disease, reason for HPN (life prolonging, quality of life 
improving or maintaining), duration of HPN, characteristics of the HPN program (day of 
infusion per week and hours of individual infusion) and functional status, were collected by 
the treating clinicians. 
Statistical analysis 
The HPN-QOL© was scored according to scoring rules previously reported (17). When 
more than 50% of items in a scale or for the whole questionnaire were missing, the scale 
score or the questionnaire were dropped from analysis on a patient basis; when the 
number of missed items was ≤ 50% for a single scale, the mean of the completed items 
was used for simple imputation. Scores were rescaled to range from 0 to 100 and, to 
further improve readability, made uniform inasmuch as high scores indicate “good 
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condition” in all scales (i.e. high function/good status as well as low symptom or problem 
intensity). 
Psychometric analyses (Aim 1 of the study) evaluated the following aspects: data 
completeness, convergent /discriminant validity and internal-consistency reliability. Data 
completeness was measured by the percentages of missing scale scores. Convergent and 
discriminant validity were assessed through multitrait-scaling analysis (18) which explores 
the relationships of each item and the hypothesized scales. Convergent validity indicates a 
relevant correlation between an item and the scale to which it belongs. Correlations were 
corrected for overlap. Pearson correlation coefficients ≥0.4 support convergent validity 
(18). Discriminant validity is supported whenever a correlation between an item and its 
hypothesized scale is higher than the correlation with the other scales. Internal-
consistency reliability of multi-item scales was measured by Cronbach's alpha; alpha 
values above 0.7 are generally regarded as acceptable for group comparison (18). 
Psychometric analyses were performed on the overall sample and within the three largest 
language subsamples: English, French and Italian. Items not fitting with the predefined 
psychometric criteria on the overall sample were candidates for dropping or modification.  
Aims 2 and 3 of the study were addressed with the use of a multivariable linear regression 
models in which the overall QOL assessment identified by the item 44 (how has your QOL 
been in the last week?) was the dependent variable. In a first analysis (“main model”) the 
following variables were considered as predictors: HPN treatment duration (classified as 
short or long using a 24-month cut-point), age (continuous covariate), gender, living status, 
functional status and presence of a stoma.  Language and underlying disease (categorical 
covariates) were modelled in the regressions using dummy variables. Stepwise backward-
deletion of non-significant regression covariates was used. This analysis was carried out in 
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the set of 451 records with complete information. A second analysis (“extended model”) 
was carried out in a set of 424 records that in addition contained a number of HPN details 
(indication, type of supply, days and hours of infusion). Although of clinical interest, these 
features are likely to reflect treatment decisions that had been based on patient and 
disease characteristics, and may thus originate some degree of confounding. Therefore, 
we followed a “two-step” strategy in which the first modelexplored prognostic effects of 
patient and disease characteristics, and the second included the effect of treatment details 
while adjusting for the other factors. Results are reported in terms of estimated regression 
coefficients (beta), corresponding 95% confidence limits (95% CLs) and overall p values at 
the Wald’s test, respectively for the main and extended models. The conventional two-
sided 5% level was chosen as the threshold of statistical significance. Statistical analyses 
were carried out with SAS (version 9.2, SAS Institute, Cary, NC) and R software (version 
3.1.1, R Foundation for Statistical Computing, Vienna, Austria).  
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Results 
Patient characteristics 
Six hundred and ninety-nine patients accepted to participate into the study and returned 
the questionnaire. Statistical analyses included 691 patients, after excluding eight 
questionnaires with more than 50% missing items.  
More patients were female (61.6%) than male, with a median age of 54 years (range, 17-
94) and with a varied geographical distribution (Table 1); 65.7% were either married or 
living with a partner and 95 (17%) were living alone; most patients (92.2%) had received at 
least compulsory school education. The underlying disease leading to CIF and HPN 
included 158 (26.3%) Crohn’s disease, 105 (17.4%) motility disorders, 102 (16.9%) 
mesenteric ischaemia, 47 (7.8%) radiation enteritis, 38 (6.3%) cancer, 152 (25.3%) ‘other’; 
89 had missing diagnoses. The reason for HPN was to prolong life in 230 patients (45.3% 
of total), to improve QOL in 175 (34.4%) and to maintain QOL in 103 (20.3%) (remaining 
data was missing). Duration of HPN infusion was <2 years in around one third of patients 
and >10 years in 26.4%. Regarding functional status, 170 (29.7%) of patients required 
some or total help. 
Despite various reminders to participating centres, many socio-demographic and clinical 
data collection forms were not returned thus resulting in missing data. 
 
Psychometric evaluation of the HPN-QOL©  
Preliminary multitrait-scaling and internal consistency analyses indicated a bad fit of items 
4 (burden of HPN), 20 (ability to socialize), 30 (nausea and vomiting) and 41 (bowel 
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movements) with respect to the original questionnaire structure. These items were 
therefore excluded from their respective scales (CO, PF, GI and NoST) and regarded as 
single item scales (Table 2). The two 0-10 NRS items assessing the effect of illness and 
the effect of HPN on global QOL showed 11% and 12% of missing data, respectively . 
These figures match with results from the previous validation study where patients 
reported a difficulty to distinguish between the effect of illness and of HPN on QOL (16). 
For these reasons the two items were dropped from the analysis.  
Results of psychometric analyses carried out on the modified questionnaire structure are 
shown in Table 2. Most scale-specific average scores were consistently around 60 to 70, 
with the exception of sexual function, holiday/travel, employment and physical function 
which scored below 50. Item level missing-value rates -not shown in Table 2- were low, 
ranging from 0% to 6%, except for the two items related to sex (17% and 20% missing). 
Accordingly, completeness was good for most scales (Table 2), the only exception being 
sexual function (17% of missing), likely because of sensitivity issues in this area for some 
patients. Lower boundaries of item-internal consistency ranges indicate that all items in the 
questionnaire showed a satisfactory correlation with their own scale (≥0.4), with the only 
exception of items 42 (“difficulty with bowel movements”) and 43 (“painful bowel 
movements”) in the No-stoma scale (0.38 internal correlation). Item-discriminant validity 
correlation figures (Table 2) were also satisfactory for all the comparisons performed. QOL 
NRS in particular yielded a median correlation with other scales of 0.32, data not reported 
in table (range 0.14-0.53, 5 correlations>0.4); given the content of the scale,  fairly high 
values were expected and may be considered acceptable. Internal consistency reliability 
was good for most of the multi-item scales, with Cronbach’s α coefficients generally higher 
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than the 0.70 benchmark, or only slightly below the benchmark for EM (α=0.65), GI 
(α=0.66), PA (α=0.65) and noST (α=0.54).  
Psychometric evaluation of the HPN-QOL© in the different  English, French and Italian 
language patient sub-groups (Supplementary Tables A1, A2 and A3) provided results 
similar to those in the overall sample, thus confirming the good quality of these cultural 
adaptations.  
Investigation of QOL associated factors 
Results of the multivariable linear regression modelling are shown in Table 3. In the “main 
model” age, gender, functional status, presence of stoma and language failed to achieve 
statistical significance. Better overall QOL scores were observed in patients with HPN 
duration longer than 24 months compared to patients with shorter duration (beta=0.55, 
95%CL: 0.12 – 0.98; P=0.013). With the procedure described in the Methods Section, two 
clusters were detected for underlying disease in terms of outcome. Better QOL was 
observed in patients with Crohn’s disease or mesenteric ischaemia compared to patients 
with other diseases (cancer, motility disorders, radiation enteritis or unspecified 
conditions). The corresponding beta coefficient was 0.65 (95% CL:0.25 – 1.06; P=0.002). 
Patients living alone tended to be disadvantaged in terms of QOL outcome compared to 
patients not living alone (beta=−0.64, 95%CL: −1.18, – 0.10; P=0.021). The whole profiles 
of standardized scale-specific scores according to HPN duration, underlying disease and 
living status are shown in Figures 1 to 3.  
The “extended model”, investigating the role of the HPN characteristics adjusted for the 
other factors showed a significant result only for HPN days of infusion per week. In 
15 
 
particular, the negative coefficient denoted a worsening overall QOL for an increasing 
number of infusion days. 
 
Discussion  
This paper represents the final stage of developing the HPN-QOL©, carried out on behalf 
of the HAN&CIF Special Interest Group of ESPEN. It started with a review of the 
instruments used to assess QOL of adult patients with CIF receiving HPN and an 
evaluation of the state of art of this topic (3,19) and then progressed with generation of 
QOL issues, production of a provisional questionnaire and its pre-testing (16). The scale 
structure of the questionnaire was initially tested for reliability and validity in a preliminary 
sample of 100 patients and showed positive results under the psychometric and clinical 
profile (17). 
The present study went further by analyzing the psychometric properties of the 
questionnaire in a wider multi-language sample. In particular, multitrait-scaling and internal 
consistency analyses indicated a good fit with respect to the original questionnaire 
structure for most items. Exceptions were items 4 (burden of HPN), 20 (ability to socialize), 
30 (nausea and vomiting) and 41 (bowel movements) which failed to upload to their 
respective scales and are better considered as separate single item scales. Also items 42 
(“difficulty with bowel movements”) and 43 (“painful bowel movements”) in the No-stoma 
scale showed borderline internal correlation (0.38). The explanation for the poor 
consistency of these items is only hypothetical and probably reflects the heterogeneity of 
patients’ population on HPN. For instance, patients with a low burden of disease-related 
symptoms may overestimate the burden related to the management of HPN, in contrast to 
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patients requiring an intensive care for their primary disease/condition who may 
understand HPN as an invaluable help and willingly accept it. A similar explanation may 
apply for the items regarding “bowel movements” since some patients (ie those on HPN for 
chronic intestinal obstruction) may consider “frequent bowel movements” a positive event 
whereas for others (e.g. patients with short bowel syndrome) it might represent the 
premise for a further increase of the HPN volume, hours and/or days of infusion to 
compensate for the excessive fluid loss. Item discriminant validity analysis showed 
satisfactory correlation figures for all the comparisons performed; this confirms the non-
overlapping meaning of distinct scales. Finally psychometric evaluation of the HPN-QOL© 
in the English, French and Italian language patient sub-groups provided results quite 
similar to those in the overall sample,  confirming the psychometric equivalence of the 
questionnaire in the three language versions.  
The “main model” of the multivariable linear regression showed that QOL score was 
significantly dependent on the type of the underlying disease, the duration of the HPN 
treatment and the living status. The “extended model” indicated that, when adjusted for 
factors identified by the “main model”, the number of days of HPN per week has also a 
significant impact of QOL. Better QOL scores were observed in patients with Crohn’s 
disease or mesenteric ischemia compared to patients with other kinds of disease (cancer, 
motility disorders, radiation enteritis or unspecified conditions). By showing better overall 
QOL in patients with longer HPN duration, this study is in agreement with the results of 
previous works (20, 21) indicating that patients are able to cope with their illness over time 
with a possible improvement in QOL. Although reasonable, this interpretation must be 
taken with caution considering that the cross-sectional study design does not allow the 
more direct assessment of time trends that would be possible with a longitudinal design. 
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QOL is influenced by both the gastrointestinal illness and the effects of HPN treatment. To 
disentangle these effects, it would be necessary to prospectively study QOL scores in a 
cohort of patients who are candidates for HPN, prior to and after HPN. Such evidence 
cannot be achieved by a cross-sectional study like the present one. The finding that living 
alone is associated with worst QOL scores was also expected and can be explained by the 
complex technology of HPN administration that requires expertise in managing needles 
and bags with sterility as well as the invaluable role of an always available caregiver.  
A number of studies have assessed QOL of patients requiring HPN but care must be taken 
when comparing their results with ours, as the majority of these studies relied on generic 
QOL tools that were neither tailored to nor validated in this patient population (19). 
The actual role of HPN characteristics on QOL of patients with CIF, such as days of 
infusion per week and hours of infusion per day, is a key question. Indeed, HPN is the 
primary therapy of CIF and therefore is dependent on the characteristics of the underlying 
disease as well as pathophysiological mechanism of CIF (1). In a previous short term 
prospective follow up study on a small patient population, where QOL assessment was 
performed using the SF-36, a generic assessment tool, it was observed that the reduction 
of QOL was associated with an increase of HPN days of infusion per week. That result 
was considered to represent a deterioration of the intestinal failure (22). Nevertheless, the 
data of the present study indicate that, when adjusted for the major factors influencing 
QOL, the number of HPN infusion per week has a significant role. This  agrees with data of 
a study on patients with short bowel syndrome, where QOL was assessed using a 
validated SBS-QoLTM scale (23). In this cohort of patients, having the same underlying 
disease characteristics, the reductions in volume of HPN infusion (and therefore of hours 
and/or days of infusions) were associated with improvements in QOL scores. In 2014, the 
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ESPEN HAN&CIF group carried out an international multicentre study aimed to identify the 
top 3 most important outcome indicators (out of a list of 9 proposed), according to patients’ 
perspectives (24). QOL was the third of the top 3 indicators, the incidence of catheter-
related infection and survival rate being the first two. Interestingly, for one of the nine 
outcome indicators (freedom and independence), there was a significant difference among 
patients categories based on HPN regimen (number of HPN day per week) and on HPN 
experience. Independence was rated more important for less experienced patients (HPN 
duration <2 years). Most of the less experienced patients received HPN on 7 days per 
week, whereas experienced patients had between 3 and 6 HPN days per week. 
Concerning the HPN regimen, patients with 6 or 7 HPN days consistently found 
independence important. This was not the case for patients with 5 HPN days or less per 
week (24). Patients were also asked to propose new indicators. Among those, two new 
indicators related to QOL were identified “keeping the problems related to my underlying 
disease as low as possible” and “maximizing HPN-free days” (24). Overall, our results and 
those from previous studies suggest that the burden of the underlying disease plays a 
primary role in determining QOL of patients on HPN for CIF and that, after optimizing the 
disease control, QOL could be further improved by reducing the HPN burden as much as 
possible. 
There are a few limitations of this study. In the first place, information on socio-
demographic and clinical data was not complete for as much as 35.5% of the patients 
originally entered into the study. This was due to administrative problem in some centres 
which performed only patient reported outcome assessment with HPN-QOL©. Secondly, in 
spite of the considerable overall sample size, the number of patients for some language 
versions (German, Dutch, Danish, Polish and Spanish) was too small for distinct 
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psychometric testing. More language specific data will be likely available if the HPN-QOL© 
becomes embedded into routine clinical practice. The measurement of QOL should be 
included in the list of clinical quality indicators identified as part of the global attempt at 
raising the quality of clinical care (18); particularly since most patients are provided with 
HPN to either maintain or improve QOL. Finally, our cross-sectional study design could not 
address HPN-QOL© questionnaire’s test-retest reliability and responsiveness to change, 
and these aspects will therefore have to be assessed in future studies. 
In conclusion, this investigation responds to the lack of evidence regarding QOL 
assessment in patients undergoing HPN, and has the potential to integrate ESPEN 
guidelines. The results have both theoretical and practical implications. Many clinical 
services are inviting patients to respond to Patient Reported Outcome Measures including 
QOL and satisfaction with the service they receive. By embedding the assessment of QOL 
into routine clinical care clinicians will be provided with the necessary outcome evidence 
that ensures good patient centred care (25). Finally, the HPN-QOL© here presented may 
also be used as a research tool in clinical trials.  
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Table 1: Socio-demographic and clinical  
patient-characteristics 
  
 
N % 
Overall 691 100.0 
Gender 
  Female 348 61.6 
Male 217 38.4 
Missing 126 - 
Age, years 
  Median (range) 54  (17 – 94) 
Marital status 
  Married/with partner 341 65.7 
Separated/divorced/widow
ed 55 10.6 
Single 123 23.7 
Missing 172 - 
Living status 
  Alone 95 17.5 
With family 413 76.2 
With other adults 34 6.3 
Missing 149 - 
Education 
  Less than compulsory 35 7.8 
Compulsory school 189 42.4 
Post compulsory 155 34.8 
University 67 15.0 
Missing 245 - 
Employment 
  Student 19 4.3 
Unemployed 107 23.9 
Homemaker 43 9.6 
Self employed 7 1.6 
Part time 51 11.4 
Full time 60 13.4 
Retired 135 30.2 
Other 25 5.6 
Missing  244 - 
Underlying Disease 
  Cancer 38 6.3 
Crohn’s disease 158 26.3 
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Mesenteric ischaemia 102 16.9 
Motility disorders 105 17.4 
Radiation Enteritis 47 7.8 
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Table 1 (continued) 
 
N % 
Other 152 25.3 
Missing 89 - 
Predominant indication for 
HPN 
  Short gut 346 60.8 
Fistula 12 2.1 
Obstruction 122 21.4 
Other 89 15.7 
Missing 122 - 
HPN duration 
  1-2 months 9 1.5 
3-12 months 93 15.5 
13-24 months 95 15.8 
25-60 months 119 19.9 
61-120 months 125 20.9 
more than 120 months 158 26.4 
Missing 92 - 
HPN supply 
  Total 165 29.4 
Supplemental 397 70.6 
Missing 129 - 
HPN days of infusion per week 
  Median (range) 5.6   (2-7) 
Missing 128 
 HPN hours of infusion per day 
  2-11 hours  190 31.8 
12-13 hours 290 48.5 
More than 13 hours 118 19.7 
Missing 93 
 Functional status 
  Independent 425 70.3 
Some help 143 23.6 
Total help 37 6.1 
Missing 86 - 
Country 
  United Kingdom 127 18.4 
Italy 117 16.9 
United States 81 11.7 
28 
 
France 76 11.0 
Netherlands 64 9.3 
Spain 43 6.2 
Germany 40 5.8 
Belgium 35 5.1 
 
Table 1 (continued) 
 
N % 
Poland 35 5.1 
Canada 32 4.6 
Denmark 20 2.9 
New Zealand 12 1.7 
Australia 9 1.3 
Missing - - 
Abbreviations: 
HPN: home parenteral nutrition 
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Table 2: Results of Item Scaling and Reliability: overall sample (N = 691) 
 
Scale kb Mean SD Missing % 
Item-Internal 
Consistencyc 
Item-Discriminant 
 Validityd Reliability
e 
Immobility (IM) 5 68 25 1  0.50 - 0.73  0.03 - 0.49 0.84 
Emotional Function (EF) 4 63 25 0  0.60 - 0.66  0.02 - 0.48 0.81 
Physical Function (PF) 3 48 26 6  0.52 - 0.69 -0.04 - 0.59 0.78 
Ability to Holiday/Travel (HT) 2 34 26 5 0.83  0.01 - 0.30 0.91 
Coping (CO) 2 58 27 2 0.57  0.07 - 0.57 0.73 
Ability to Eat/Drink (ED) 2 62 26 4 0.55 -0.04 - 0.36 0.71 
Employment (EM) 2 36 32 5 0.49 -0.09 - 0.36 0.65 
Sexual Function (SF) 2 22 25 17 0.63  -0.07 - 0.25 0.77 
Body Image (BI) 2 66 33 1 0.76 -0.01 - 0.44 0.86 
Fatigue (FA) 2 52 31 0 0.84  0.01 - 0.55 0.91 
Gastrointestinal Symptoms (GI) 2 64 29 4 0.49 -0.07 - 0.29 0.66 
Pain (PA) 2 64 29 0 0.48  0.04 - 0.41 0.65 
Presence of Stoma (ST) 2 70 29 3 0.70 -0.05 - 0.39 0.82 
Absence of Stoma (NoST) 2 79 26 5 0.38 -0.01 - 0.38 0.54 
Nutrition Team (NT) 1 77 31 4 - -0.05 - 0.14 - 
Ambulatory Pump (AP) 1 65 36 0 - -0.02 - 0.22 - 
General Health (GH) 1 75 24 2 -  0.06 - 0.32 - 
Weight (WT) 1 70 33 0 - -0.05 - 0.38 - 
Sleep Pattern (SP) 1 60 35 0 -  0.01 - 0.35 - 
Financial Issue (FI) 1 75 32 6 - -0.09 - 0.26 - 
Burden of HPN (item 4) 1 66 30 1 -  0.05 - 0.50 - 
Ability to socialize (item 20) 1 50 33 2 - -0.10 - 0.23 - 
Nausea and vomiting (item 30)  1 74 32 0 -  0.06 - 0.35 - 
Bowel movements (no stoma) (item 
41) 1 46 33 5 - -0.29 - 0.19 - 
QOL Numeric Rating Scale 
(NRS) 1 58 21 3 -  0.14 - 0.53 - 
30 
 
b Number of items c Range of correlations between items in the scale 
d Range of correlations between each item in the scale and other scales 
e Internal-consistency reliability (Cronbach’s alpha) 
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Table 3: Multivariable regression modelling used to 
investigate the factors associated with overall QOL 
Category (reference) Beta (95% CI) P 
Main model (N=451) § 
Age, years 
  IQ range: 44-64 -0.9 (-3.6  –   1.9) 0.543 
Gender 
  Male (female) 0.4 (-3.7  –   4.4) 0.862 
Underlying disease 
  Crohn’s/Ischaemia 
(other)  6.5 ( 2.5  –   10.6) 0.002 
Living status 
  Alone (not alone) -6.4 (-11.8  – -1.0) 0.021 
Functional status 
  Some help 
(indepedent) -1.6 (-6.3  –  3.1) 0.700 
Total help 
(independent)  1.6 (-6.8  –  9.9) 
 Stoma 
  Yes (no) -3.7 (-7.7  –  0.3) 0.073 
HPN duration 
  Long (short) 5.5 (1.2  –  9.8) 0.013 
Language 
  French (English) 3.6 (-2.1  –  9.3) 0.053 
Italian (English) -3.1 (-8.9  –  2.6) 
 Other (English)  3.8 (-1.6  –  9.2) 
 Extended model (N=424) § 
Indication 
  Obstruction (short gut) -1.3 (-7.7  –  5.2) 0.468 
32 
 
Other/fistula (short gut)  -4.1 (-10.7  –  2.5) 
 HPN supply 
  Total (supplemental) 2.2 (-2.8  –  7.2) 0.392 
HPN days of infusion per week 
  IQ range: 4-7 -4.7 (-8.9  – -0.5) 0.028 
HPN hours of infusion per day 
  12-13 (<12) -5.1 (-10.5  –  0.3) 0.140 
>13 (<12) -5.7 (-12.2  –  0.8) 
 § Main model: HPN characteristics excluded because dependent 
on the underlying disease 
§ Extended model: assessment of the HPN characteristics 
adjusted for the remaining factors 
Abbreviations: 
QOL: quality of life 
CI: confidence interval 
IQ: interquartile 
HPN: home parenteral nutrition 
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Figure 1 Profiles of standardized scale scores according to HPN duration, underlying disease and living status 
 
  
34 
 
 
Figure 2 profiles of standardized scale scores according to underlying disease  
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Figure 3 Profiles of standardized scale scores according to living status 
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Supplementary Table A1: Item Scaling and Reliability: English language sample(N = 229) 
Scale kb Mean SD8 Missing % 
Item-Internal 
Consistencyc 
Item-Discriminant 
 Validityd Reliability
e 
Immobility (IM) 5 65 27 0 0.53 - 0.75  0.00 - 0.57 0.85 
Emotional Function (EF) 4 57 26 0 0.58 - 0.64  0.03 - 0.61 0.80 
Physical Function (PF) 3 48 26 0 0.48 - 0.71 -0.02 - 0.69 0.78 
Ability to Holiday/Travel (HT) 2 34 26 1 0.80 -0.02 - 0.36 0.89 
Coping (CO) 2 64 27 0 0.61 -0.06 - 0.59 0.76 
Ability to Eat/Drink (ED) 2 64 26 0 0.46 -0.06 - 0.41 0.63 
Employment (EM) 2 35 35 3 0.59 -0.09 - 0.50 0.74 
Sexual Function (SF) 2 21 24 8 0.59 -0.14 - 0.33 0.74 
Body Image (BI) 2 67 33 0 0.75  0.04 - 0.46 0.86 
Fatigue (FA) 2 43 31 0 0.86  0.00 - 0.55 0.93 
Gastrointestinal Symptoms (GI) 2 67 29 0 0.45  0.00 - 0.50 0.63 
Pain (PA) 2 56 30 0 0.46 -0.05 - 0.49 0.63 
Presence of Stoma (ST) 2 67 30 1 0.75 -0.03 - 0.49 0.86 
Absence of Stoma (noST) 2 75 26 3 0.30 -0.17 - 0.51 0.46 
Nutrition Team (NT) 1 73 33 6 - -0.07 - 0.26 - 
Ambulatory Pump (AP) 1 74 32 0 - -0.05 - 0.30 - 
General Health (GH) 1 78 22 3 - -0.09 - 0.38 - 
Weight (WT) 1 68 33 0 -  0.04 - 0.38 - 
Sleep Pattern (SP) 1 48 35 0 -  0.06 - 0.36 - 
Financial Issue (FI) 1 69 35 2 - -0.10 - 0.29 - 
Burden of HPN (item 4) 1 59 32 1 -  0.04 - 0.59 - 
Ability to socialize (item 20) 1 57 28 0 -  0.03 - 0.58 - 
Nausea and vomiting (item 30)  1 69 34 0 -  0.03 - 0.48 - 
Bowel movements (no stoma) (item 
41) 1 31 32 3 - -0.23 - 0.18 - 
QOL Numeric Rating Scale 
(NRS) 1 59 23 3 -  0.17 - 0.63 - 
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b Number of items c Range of correlations between items in the scale 
d Range of correlations between each item in the scale and other scales 
e Internal-consistency reliability (Cronbach’s alpha) 
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Supplementary Table A2: Results of Item Scaling and Reliability: French language sample (N = 143) 
Scale kb Mean SD Missing % 
Item-Internal 
Consistencyc 
Item-Discriminant 
 Validityd Reliability
e 
Immobility (IM) 5 70 23 2 0.36 - 0.72 -0.15 - 0.56 0.80 
Emotional Function (EF) 4 66 26 0 0.65 - 0.70 -0.11 - 0.51 0.84 
Physical Function (PF) 3 43 27 2 0.49 - 0.70 -0.08 - 0.65 0.75 
Ability to Holiday/Travel (HT) 2 36 29 10 0.87 -0.05 - 0.29 0.93 
Coping (CO) 2 60 29 1 0.53 -0.07 - 0.62 0.69 
Ability to Eat/Drink (ED) 2 61 26 0 0.62 -0.09 - 0.43 0.77 
Employment (EM) 2 43 30 8 0.47 -0.17 - 0.56 0.64 
Sexual Function (SF) 2 26 26 11 0.59 -0.24 - 0.32 0.74 
Body Image (BI) 2 67 32 1 0.75 -0.23 - 0.52 0.86 
Fatigue (FA) 2 55 30 0 0.79  0.06 - 0.60 0.88 
Gastrointestinal Symptoms (GI) 2 74 28 0 0.45 -0.12 - 0.46 0.62 
Pain (PA) 2 67 28 0 0.40 -0.14 - 0.43 0.58 
Presence of Stoma (ST) 2 73 33 7 0.72 -0.21 - 0.48 0.84 
Absence of Stoma (noST) 2 83 25 5 0.45 -0.11 - 0.42 0.63 
Nutrition Team (NT) 1 72 31 3 - -0.08 - 0.23 - 
Ambulatory Pump (AP) 1 68 38 0 - -0.14 - 0.45 - 
General Health (GH) 1 75 20 1 - -0.02 - 0.43 - 
Weight (WT) 1 77 32 1 - -0.14 - 0.37 - 
Sleep Pattern (SP) 1 63 35 1 -  0.02 - 0.35 - 
Financial Issue (FI) 1 82 27 5 - -0.21 - 0.30 - 
Burden of HPN (item 4) 1 74 30 2 -  0.01 - 0.40 - 
Ability to socialize (item 20) 1 57 33 3 - -0.05 - 0.41 - 
Nausea and vomiting (item 30)  1 74 34 0 - -0.08 - 0.54 - 
Bowel movements (no stoma) (item 
41) 1 43 32 4 - -0.12 - 0.36 - 
QOL Numeric Rating Scale (NRS) 1 60 21 1 -  0.05 - 0.56 - 
b Number of items  
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c Range of correlations between items in the scale 
d Range of correlations item between each item in the scale and other scales 
e Internal-consistency reliability (Cronbach’s alpha) 
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Supplementary Table A3: Results of Item Scaling and Reliability: Italian language sample (N = 117) 
Scale kb Mean SD Missing  % 
Item-Internal 
Consistencyc 
Item-Discriminant 
 Validityd Reliability
e 
Immobility (IM) 5 70 21 0 0.50 - 0.82 -0.35 - 0.66 0.85 
Emotional Function (EF) 4 62 25 0 0.52 - 0.72 -0.25 - 0.53 0.81 
Physical Function (PF) 3 55 22 3 0.45 - 0.73 -0.34 - 0.55 0.79 
Ability to Holiday/Travel (HT) 2 34 24 0 0.86 -0.30 - 0.42 0.93 
Coping (CO) 2 48 23 5 0.28 -0.45 - 0.74 0.44 
Ability to Eat/Drink (ED) 2 59 22 2 0.66 -0.50 - 0.50 0.79 
Employment (EM) 2 29 26 8 0.24 -0.42 - 0.32 0.39 
Sexual Function (SF) 2 19 25 28 0.66 -0.22 - 0.55 0.76 
Body Image (BI) 2 59 35 0 0.86 -0.09 - 0.52 0.92 
Fatigue (FA) 2 64 25 0 0.85 -0.28 - 0.67 0.92 
Gastrointestinal Symptoms (GI) 2 48 23 2 0.62 -0.46 - 0.17 0.77 
Pain (PA) 2 71 28 0 0.59 -0.24 - 0.45 0.75 
Presence of Stoma (ST) 2 72 25 5 0.58 -0.38 - 0.48 0.74 
Absence of Stoma (noST) 2 78 30 3 0.59 -0.30 - 0.45 0.70 
Nutrition Team (NT) 1 78 30 0 - -0.14 - 0.27 - 
Ambulatory Pump (AP) 1 63 34 0 - -0.25 - 0.24 - 
General Health (GH) 1 79 26 2 - -0.24 - 0.40 - 
Weight (WT) 1 70 31 0 - -0.13 - 0.40 - 
Sleep Pattern (SP) 1 71 32 0 - -0.24 - 0.48 - 
Financial Issue (FI) 1 80 31 12 - -0.34 - 0.40 - 
Burden of HPN (item 4) 1 70 27 0 - -0.18 - 0.53 - 
Ability to socialize (item 20) 1 32 34 5 - -0.63 - 0.28 - 
Nausea and vomiting (item 30)  1 84 25 0 - -0.24 - 0.44 - 
Bowel movements (no stoma) (item 
41) 1 59 32 3 - -0.70 - 0.48 - 
QOL Numeric Rating Scale 
(NRS) 1 54 21 5 - -0.18 - 0.57 - 
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b Number of items 
c Range of correlations between items in the scale 
d Range of correlations item between each  item in the scale and other scales 
e Internal-consistency reliability (Cronbach’s alpha) 
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